Corbus Pharmaceuticals Holdings (CRBP) Return on Capital Employed (2014 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) recorded quarterly Return on Capital Employed of 35.94% in Q3 2025, down 21.51% quarter-over-quarter from 29.57% in Q2 2025, and down 3213.0% on a YoY basis from 1.15% in Q3 2024.
Corbus Pharmaceuticals Holdings (CRBP) Return on Capital Employed (2014 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Return on Capital Employed history runs 12 years deep, the most recent figure standing at 35.94% for Q3 2025.
- In Q3 2025, Return on Capital Employed fell 3213.0% year-over-year to 35.94%; the TTM figure through Sep 2025 stood at 35.94% (down 3213.0% YoY), while the FY2024 annual figure was 7.86%, up 30062.0% from the prior year.
- Return on Capital Employed was 35.94% for Q3 2025 at Corbus Pharmaceuticals Holdings, down from 29.57% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 4.26% in Q4 2024 to a low of 11748.17% in Q4 2023.
- Historically, Return on Capital Employed has averaged 697.17% across 5 years, with a median of 61.07% in 2022.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed tumbled 1167881 bps in 2023, then soared 1175243 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 57.93% in 2021, then retreated by 20 bps to 69.36% in 2022, then slumped by 16838 bps to 11748.17% in 2023, then jumped by 100 bps to 4.26% in 2024, then tumbled by 944 bps to 35.94% in 2025.
- The last three Return on Capital Employed figures came in at 35.94% (Q3 2025), 29.57% (Q2 2025), and 10.63% (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -107.40% |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -50.43% |
| 10 | Corbus Pharmaceuticals Holdings | 133.67 Mn | 105.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -35.94% |
| Jun 30, 2025 | -29.57% |
| Mar 31, 2025 | -10.63% |
| Dec 31, 2024 | 4.26% |
| Sep 30, 2024 | -3.81% |
| Jun 30, 2024 | -14.77% |
| Mar 31, 2024 | -52.37% |
| Dec 31, 2023 | -11,748.17% |
| Sep 30, 2023 | -540.96% |
| Jun 30, 2023 | -142.07% |
| Mar 31, 2023 | -108.95% |
| Dec 31, 2022 | -69.36% |
| Sep 30, 2022 | -64.55% |
| Jun 30, 2022 | -61.07% |
| Mar 31, 2022 | -56.70% |
| Dec 31, 2021 | -57.93% |
| Sep 30, 2021 | -64.89% |
| Jun 30, 2021 | -77.84% |
| Mar 31, 2021 | -110.99% |
| Dec 31, 2020 | -182.84% |